Weekly funding Opportunities and NIH Grant Writing Workshop

[Med Research]

NIH Grant Writing Workshop – SAVE THE DATE
The FSU Office of Research Development (ORD) is partnering with FAMU to offer a free two day intensive NIH grant writing workshop.  The workshop will be held April 20-21, 2020.  The location and registration site are still in development, but ORD will provide more information soon.

Congressionally Directed Medical Research Programs
Autism Research Program<https://cdmrp.army.mil/funding/arp>
Clinical Trial Award
Pre-application: April 15, 2020. Invited full application: July 16, 2020.
Idea Development Award
Pre-application: April 15, 2020. Invited full application: July 16, 2020.
Clinical Translational Research Award
Pre-application: April 15, 2020. Invited full application: July 16, 2020.
Med-RA deadline to receive draft documents for April 15, 2020 pre-applications: April 1.
Ovarian Cancer Research Program<https://cdmrp.army.mil/funding/ocrp>
Clinical Translational Research Award
Pre-application: April 23, 2020. Application: July 30, 2020.
Investigator-Initiated Research Award
Pre-application: April 23, 2020. Application: July 30, 2020.
Ovarian Cancer Academy Award - Early Career Investigator
Pre-application: April 23, 2020. Application: July 30, 2020.
Pilot Award
Pre-application: April 23, 2020. Application: July 30, 2020.
Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14.
Peer Reviewed Medical Research Program<https://cdmrp.army.mil/funding/prmrp>
Topic Areas: Arthritis, Burn Pit Exposure, Chronic Migraine and Post-Traumatic Headache, Congenital Heart Disease, Constrictive Bronchiolitis, Diabetes, Dystonia, Eating Disorders, Emerging Viral Diseases, Endometriosis, Epidermolysis Bullosa, Familial Hypercholesterolemia, Fibrous Dysplasia, Focal Segmental Glomerulosclerosis, Food Allergies, Fragile X, Frontotemporal Degeneration, Guillain-Barré Syndrome, Hemorrhage Control, Hepatitis B, Hydrocephalus, Immunomonitoring of Intestinal Transplants, Inflammatory Bowel Diseases, Interstitial Cystitis, Metals Toxicology, Mitochondrial Disease, Musculoskeletal Health, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Myotonic Dystrophy, Nutrition Optimization, Pancreatitis, Pathogen-Inactivated Blood Products, Plant-Based Vaccines, Polycystic Kidney Disease, Pressure Ulcers, Pulmonary Fibrosis, Resilience Training, Respiratory Health, Rheumatoid Arthritis, Sleep Disorders and Restriction, Spinal Muscular Atrophy, Sustained Release Drug Delivery, Vascular Malformation, Women’s Heart Disease
Discovery Award
Pre-application (letter of intent): April 16, 2020. Application: April 30, 2020.
Focused Program Award
Pre-application (preproposal): April 23, 2020. Application: August 6, 2020.
Investigator-Initiated Research Award
Pre-application (preproposal): April 23, 2020. Application: August 20, 2020.
Technology/Therapeutic Development Award
Pre-application (preproposal): April 23, 2020. Application: August 20, 2020.
Med-RA deadline to receive draft documents for April 16, 2020 pre-applications: April 2.
Med-RA deadline to receive draft documents for April 23, 2020 pre-applications: April 14.

Simons Foundation Autism Research Initiative: Summer 2020 Pilot Award<https://www.sfari.org/grant/pilot-awards-request-for-applications/>
Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is $300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years.
Due April 24, 2020. Med-RA deadline to receive draft documents: April 13.

Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-036.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for May 7, 2020 standard date: April 21.

Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-116.html>
This Funding Opportunity Announcement (FOA), entitled “Toward Translation of Cancer Nanotechnology Interventions (TTNCI)” is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The “Toward Translation of Nanotechnology Cancer Interventions” (TTNCI) awards are designed to mature experimental nanomedicines relying on “next-generation” nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Due May 21, 2020; November 19, 2020; May 20, 2021; and November 18, 2021. Med-RA deadline to receive draft documents for May 21, 2020 deadline: May 11.

Supporting Primary Care to Advance Cardiovascular Health in States with High Prevalence of Preventable CVD Events (U18)<https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-20-002.html>
The Agency for Healthcare Research and Quality (AHRQ) seeks applications to disseminate and implement patient-centered outcomes research (PCOR) findings directly to primary care practices and support practices in implementing PCOR clinical and organizational findings. Applicants are expected to develop sustainable, State-based quality improvement support capacity through partnership with State and local organizations, build and engage a network of primary care practices, disseminate PCOR findings on heart health, and increase the capacity of primary care practices to implement evidence in the future.
Due May 22, 2020. Med-RA deadline to receive draft documents: May 11.

NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-063.html>
This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.
The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.
Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.

NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-126.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the resource, user training and services, provision of community-generated data storage and archiving, wide dissemination of the tools and/or resources, and establishment of interoperability with other NIH bioinformatics resources.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 12.

Biomedical Technology Development and Dissemination Center (RM1 – Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-104.html>
This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Development and Dissemination (BTDD) Centers. The BTDD program supports the development of technologies once their feasibility has been established and the dissemination of these technologies to the wider biomedical research community. The program encourages investigators to propose projects that address any of the biomedical research areas within the mission of NIGMS<http://www.nigms.nih.gov/about/overview/>. The Centers are required to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Center’s technologies and results. Centers should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Potential applicants are strongly encouraged to contact NIGMS staff at least 10 weeks prior to the application due date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center.
Due May 26, 2020; January 26, 2021; May 26, 2021; January 26, 2022; May 26, 2022; and January 26, 2023. Med-RA deadline to receive draft documents for May 26, 2020 deadline: May 12.

Collaborative Program Grant for Multidisciplinary Teams (RM1 – Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-103.html>
This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.
Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate for this FOA.
Due May 27, 2020; January 27, 2021; May 27, 2021; January 27, 2022; May 27, 2022; and January 27, 2023. Med-RA deadline to receive draft documents for May 27, 2020 deadline: May 13.

NIH S10s: Shared Instrumentation Grant (SIG) Program, High-End Instrumentation (HEI) Grant Program, Shared Instrumentation for Animal Research (SIFAR) Grant Program
SIG<https://grants.nih.gov/grants/guide/pa-files/par-20-113.html>
The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated systems. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
HEI<https://grants.nih.gov/grants/guide/pa-files/par-20-114.html>
The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, high throughput robotic screening systems, and biomedical imagers.
SIFAR<https://grants.nih.gov/grants/guide/pa-files/PAR-20-112.html>
The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least $50,000, after all applicable discounts. No instrument in a cluster can cost less than $20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is $750,000.
Due June 1, 2020. Med-RA deadline to receive draft documents: May 18.

Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-053.html>
This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.
Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 / R01 Clinical Trials Not Allowed)
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-20-082.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-20-055.html>
These Funding Opportunity Announcements encourage research grant applications directed toward developing next-generation human cell-derived microphysiological systems and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.

Co-infection and Cancer (R21 / R01 Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/pa-files/par-20-061.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-20-062.html>
The purpose of these Funding Opportunity Announcements is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment
Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26.

Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-064.html>
The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.
Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.

Improving Quality of Care and Patient Outcomes During Care Transitions (R01)<https://grants.nih.gov/grants/guide/pa-files/PA-20-068.html>
The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to produce health services research that will rigorously test promising interventions aimed at improving communication and coordination during care transitions.
Standard dates apply. Expires December 6, 2022. Med-RA deadline to receive draft documents for June 5, 2020 standard date: May 26.

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 – Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/par-20-070.html>
This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Standard dates apply. Expires November 17, 2022. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-071.html>
This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Standard dates apply. Expires November 17, 2022. Med-RA deadline to receive draft documents for June 16, 2020 standard date: June 3.

Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-004.html>
This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity.
Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens.
The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID’s overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.
Due June 29, 2020. Med-RA deadline to receive draft documents: June 16.

Alzheimer’s Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-006.html>
This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer’s disease and related dementias (AD/ADRD).
Due July 1, 2020. Med-RA deadline to receive draft documents: June 18.

Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R21 / R01 Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/rfa-files/rfa-at-21-002.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-21-001.html>
This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic/lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.
Due July 9, 2020. Med-RA deadline to receive draft documents: June 25.

Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21 / R33 Clinical Trial Not Allowed) <https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-004.html>
To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.
Due July 20, 2020. Med-RA deadline to receive draft documents: July 7.

Planning Projects for Clinical Trials on Effects of Sustained Reductions in Caloric Intake and Related Dietary Practices in Younger and Older Persons (U01 Clinical Trial Optional) <https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-016.html>
This funding opportunity announcement (FOA) invites applications for 3-year planning projects for trials in either of two age ranges (25 to <50 or ≥50 years of age) to determine the effects of sustained (e.g. 5-year) caloric restriction (CR) and other interventions that modify the amount, timing, or composition of nutrient intake on risk factors for aging-related conditions and mechanisms that may influence health span and longevity. Proposed projects must plan for trials with a minimum of three arms: a control group; a CR group; and at least one other nutritional intervention that modifies level, timing, or composition of nutrient intake. Narrower age ranges within the younger and older age groups may be proposed. The projects will support organizational, planning, and protocol development activities, addressing elements such as selection and design of interventions, recruitment, eligibility criteria, selection of pre-specified study outcomes, outcome ascertainment, behavioral interventions to achieve and maintain adherence, adherence measurement, and outcome analysis. The projects will also support pilot studies and data analyses needed for these planning activities.
Due July 23, 2020. Med-RA deadline to receive draft documents: July 13.

Research Education Program Grants for CryoEM and CryoET Curriculum Development (R25 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-010.html>
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron tomography (cryoET) for structural and cell biology research. Technical advances in cryoEM have resulted in its expanded use in generating reliable atomic models of complete and fully functional macromolecular complexes. An emerging related cryoEM method, cryoET, can image macromolecular assemblies in intact unstained frozen cells in three dimensions (3-D). Together, these methods enable high-resolution analysis of previously inaccessible levels of biological organization, ranging from below 100 kD to whole cells. Currently, demand for existing training opportunities exceeds capacity. Moreover, this demand is expected to rise as adoption of cryoEM and cryoET technology continues to increase. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on addressing instructional needs for new users of cryoEM and cryoET methods by supporting the development of online and computer-based instructional materials in these technologies.
Due July 24, 2020. Med-RA deadline to receive draft documents: July 13.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-122.html>
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Due August 11, 2020; February 9, 2021; August 10, 2021; February 9, 2022; August 9, 2022; and February 9, 2023. Med-RA deadline to receive draft documents for August 11, 2020 deadline: July 29.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200309/8e195931/attachment.html>